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scored highest as reasons for not taking medications as pre-
scribed. The median PDC for antihypertensive drugs was 57%,
less than 40% had PDC >80%, with newly treated hypertensive
patients commonly =<80% PDC. 35% would be less likely or
much less likely to miss a dose if two pills would be combined
in one tablet, this likelihood was independent of CVD, experi-
enced or new use and calculated PDC levels. Perceived likeliness
to beneﬁt from a combined tablet was signiﬁcantly higher in
persons taking fewer AH drugs, and patients self-reporting
taking =<20% of doses. CONCLUSION: Patients newly treated
with antihypertensive drugs and additional cardiovascular risk
factors may beneﬁt most from a ﬁxed combination of two car-
diovascular risk reducing drugs in one pill since they express
more partial adherence and use fewer tablets.
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OBJECTIVES: Noncompliance and non-persistence with long-
term medication is a serious world-wide problem that leads to
compromised health beneﬁts and serious economic conse-
quences. A systematic literature review was conducted to
compare rates of compliance and persistence among studies 
of treatments for hypertension, dyslipidemia, and diabetes.
METHODS: A search of the literature (2000–2005) was focused
on publications that provided a numeric measure of medication
compliance and/or persistence, an adequate description of
methods, and numeric compliance and/or persistence rates for
antihypertensives (AHT), lipid-lowering therapy (LLT), or oral
antidiabetics (OAD). Studies were classiﬁed according to their
source of data into pharmacy claims and electronic monitors
(Medication Event Monitoring System, MEMS), and by study
design into retrospective and prospective studies. Results
reported as medication possession ratio (MPR) were extracted
and averaged over the treatment arms of the studies. Compliance
rates were compared across study design and treatment class.
RESULTS: The literature review resulted in 139 studies assess-
ing treatment with one or more targeted medications: AHT =53,
LLT =32, OAD =35, multiple treatments =19. Twelve-month
compliance rates averaged 67% for AHT, 74% for LLT, and
76% for OAD drugs (overall 72 ± 18%).Compliance rates aver-
aged 79% among prospective and 71% among retrospective
studies (NS). Persistence estimates at 12 months from 22 studies
ranged between 35% and 92% (mean 63 ± 18%). Thirty-ﬁve
percent of the reports related compliance to treatment outcomes.
Similar proportions were observed across classes. The propor-
tion of MEMS studies reporting outcomes related to compliance
or persistence was higher than studies based on pharmacy claims:
clinical consequences (52% vs. 18%), health care utilization
(14% vs 4%), and lower for no outcome data (33% vs. 78%)
(p = 0.004). CONCLUSION: These data indicated comparable
compliance and persistence rates across treatments for hyper-
tension, dyslipidemia, and diabetes with three-fourths of med-
ication taken as prescribed and two-thirds of patients continuing
for one year.
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OBJECTIVES: Assess prevalence and discontinuation rates 
of antidyslipidemic therapy in patients with dyslipidemia.
METHODS: We conducted a retrospective cohort study using a
large US national database of electronic medical records con-
taining diagnosis, lab and medication information. Users of 
antidyslipidemics were identiﬁed. Prevalence of six classes of
antidyslipidemics was described and one-year discontinuation
rate was calculated. Logistic regression model was used to eval-
uate factors affecting drug discontinuation. RESULTS: We iden-
tiﬁed 153,505 patients who started antidyslipidemic therapy
from 1997 to 2004 and were followed for one year after drug
initiation. Among 214,440 distinct treatment regimen initiations,
79.5% were statins, with atorvastatin (52.7%) and simvastatin
(24.0%) being the most frequently prescribed. Prevalence of
other classes of antidyslipidemics was: 8.8% for ﬁbrates, 5.3%
for cholesterol absorption inhibitors, 3.3% for niacin, 2.7% for
bile acid-binding resins, and 0.5% for combination formula-
tions. One-year discontinuation rate was 28.6% for statins,
31.8% for cholesterol absorption inhibitors, 34.1% for ﬁbrates,
40.7% for combination formulations, 44.7% for niacin, and
50.1% for bile acid-biding resins. Logistic regression showed
that statin users were less likely to stop therapy than patients on
other classes (odds ratio (OR): 0.63). Surprisingly, patients with
coronary hear disease (OR: 1.22) and diabetes (OR: 1.13) were
more likely to discontinue treatment than patients without those
conditions; high LDL-C or TG and low HDL-C were also found
to be associated with higher rates of medication discontinuation
at one year. CONCLUSIONS: Our study showed that signiﬁcant
variation exists in medication discontinuation among different
classes of antidyslipidemics. Medications targeting to raise HDL-
C or lower TG had higher discontinuation rate, implying that
there were unmet needs for the treatment of abnormal HDL-C
or TG. High discontinuation rate for patients at high risk for
cardiovascular disease was a major concern. Further studies are
needed to assess the consequences and implications of medica-
tion discontinuation.
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OBJECTIVE: To evaluate the impact of patient beliefs on med-
ication non-adherence for the purpose of crafting medication
adherence messages for disease management programs.
METHODS: In late 2005, 5630 respondents to the Thomson
Medstat PULSE health behavior survey, a nationally representa-
tive U.S. survey, reported having high cholesterol. Respondents
received additional cholesterol-speciﬁc questions beyond demo-
graphic/clinical questions already part of the survey. Beliefs
about the necessity of and concerns about taking their medica-
tions were assessed via ﬁve likert-scale questions each with
summed scores ranging between ﬁve and 25. A cut-point of 15
was used to identify high versus low necessity or concerns. Four
patient segments resulted representing high necessity/high
concern, low necessity/high concern, low necessity/low concern,
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and high necessity/low concern. Non-adherence was measured
as skipping, taking smaller doses, delaying ﬁlls or stopping ﬁlls
of a medication in the past 30 days. Reasons for non-adherence
included cost, forgetting, experience with the medication, self-
assessed need, and convenience. RESULTS: A total of 4737
respondents took a prescription cholesterol-lowering medica-
tion; 28.1% reporting at least one form of non-adherence. Rates
of non-adherence varied signiﬁcantly among the four patient seg-
ments as did demographics, types of and reasons for non-
adherence. At the univariate level, results showed that beliefs,
age younger than 65, less time on medication, non-white eth-
nicity, and lower education were associated with non-adherence.
When included in the same model, the above factors, with the
exception of time on medication, remained signiﬁcantly associ-
ated with non-adherence. Even after controlling for key demo-
graphic characteristics, these patient belief groups remained
signiﬁcantly associated with non-adherence. CONCLUSION:
Beliefs about medication necessity and concerns are relevant to
medication non-adherence allowing creation of inﬂuential mes-
saging to improve adherence behavior. Understanding belief dif-
ferences has actionable implications for disease management
programs.
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OBJECTIVE: Atrial Fibrillation (AF) is a frequent arrhythmia
that has a great impact on Health-Related Quality of Life
(HRQoL). Nowadays there is no speciﬁc questionnaire in AF, for
this reason we have developed the AF-QoL questionnaire.
METHODS: In order to deﬁne the main dimensions the ques-
tionnaire should cover, a literature review and a focus group with
three cardiologists were performed. A semi-structured interview
was conducted in 17 patients with AF to evaluate the impact of
disease, symptoms and treatment on HRQoL. From the content
of the interviews a sample of items were identiﬁed. Each item
was subsequently rated by the cardiologists, according to clarity,
frequency and importance to reduce the number of items.
Remaining items were edited in a questionnaire format and
administered to a sample of 112 patients (47.3% persistent AF
and 52.7% paroxistic AF). A factor analysis and a Rasch analy-
sis were performed to obtain the ﬁnal pilot questionnaire before
the validation study. RESULTS: After qualitative reduction, a 40
items questionnaire was obtained (AF-QOL 40). Factor analysis
identiﬁed 2 dimensions with a total variance explained of 50.2%.
Rasch analysis was used to exclude those items with inadequate
adjustment (INFIT or OUTFIT >1.30 and <0.70) or redundant
with other items in the measurement scale, obtaining a total of
18 items. This ﬁnal questionnaire (AF-QOL 18) has a good inter-
nal consistency (Cronbach’s alpha =0.91). Comparative psycho-
metric performance between AF-QOL 40 and AF-QoL 18
showed similarity in internal consistency (0.95 and 0.91), item
correlation-overall score (0.4–0.76 and 0.45–0.76) and a high
correlation between the two questionnaires (r = 0.94). CON-
CLUSION: AF-QoL is a new questionnaire of 18 items, with ini-
tially good psychometric properties though validation is needed
through a formal validation process in adequate sample size.
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OBJECTIVES: Chronic patients tend to develop different thera-
peutic strategies depending on treatment efﬁcacy, and show pref-
erence for those treatments with fewer undesired effects. It is
likely that those treatments showing best patient satisfaction
should be preferred, should increase adherence and hence beneﬁt
from pharmacological therapeutic beneﬁts. The psychometric
properties of a recently developed questionnaire of Treatment
Satisfaction (SATMED-Q) are assessed in a chronic hypertensive
population. METHODS: A sample of 1226 patients was gath-
ered by 258 clinicians from specialized hypertension units rep-
resentative of the national distribution in Spain. The following
data were collected: Sociodemographic and anthropometric
data, hypertension risk factors, concurrent diseases, pharmaco-
logical treatment, and the SATMED-Q (Treatment Satisfaction),
MOS SF-12 (HRQoL) and Morisky-Green (Adherence) ques-
tionnaires. Reliability and validity were determined. Factor
analysis was used to check the instrument original structure.
RESULTS: The original 6 factor solution explained 87.3% of the
available variance; it was well deﬁned, with 6 eigenvalues above
1, simple factor loadings above 0.89, and communalities above
0.82. Correlations between dimensions varied between 0.07 and
0.51, being the dimension of undesired medicine effects the less
related. Dimensional Cronbach’s á ranged between 0.898 and
0.946. The one-dimensional Intraclass Correlation Coefﬁcient
attained a value of 0.903 (0.894–0.911, 95% CI) and Guttman
two-half index was 0.942. Treatment Satisfaction correlations
with HRQoL were lower (r from −0.005 to 0.240) than with
adherence (r from −0.154 to −0.314). Patients with controlled
BP levels (<140/90 mmHg) showed better treatment satisfaction,
HRQoL, and adherence (p < 0.001) than those not controlled.
CONCLUSIONS: The psychometric properties of the SATMED-
Q were very good in this chronic hypertensive population. Treat-
ment satisfaction measures are more sensitive to BP control
status than HRQoL measures. Patients following an effective 
and tolerated treatment show better satisfaction and better
adherence.
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OBJECTIVES: Intra-ocular pressure (IOP) ﬂuctuation over 24
hours is an independent risk factor for glaucoma progression.
Night time IOP measurement is not a routine practice, however.
The aim of this study was to predict the chance of a nocturnal
IOP peak °Y´ 18 mmHg from measurements made during the day.
METHODS: Daytime IOP measurements obtained from three
clinical trials were pooled. The night time IOP peak was deﬁned
as the maximum value between 0:00h and 04:00h. IOP mea-
surements at 08:00h, 12:00h, 16:00h, and 20:00h were
dichotomized, using the 18 mmHg threshold reported by the
Advanced Glaucoma Intervention Study. Patient IOPs were
assessed during the pre-treatment washout period and during
